Hikal Limited Sets February 17, 2026 as Record Date for Interim Dividend Eligibility

Hikal Limited has announced the record date for its interim dividend payment for the financial year 2025-26. The pharmaceutical and specialty chemicals company has set February 17, 2026 as the cut-off date for determining shareholder eligibility for the dividend distribution. Board Approval and Regulatory Compliance The company's Board of Directors approved the interim dividend at their meeting held on February 11, 2026. Hikal has formally communicated this decision to both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Record Date Details The key details of the dividend announcement are as follows: Parameter Details Record Date Tuesday, February 17, 2026 Purpose Interim Dividend for FY 2025-26 Security Type Equity Shares BSE Code 524735 NSE Symbol HIKAL Shareholder Eligibility Shareholders who hold equity shares of Hikal Limited as of the close of business on February 17, 2026 will be eligible to receive the interim dividend for the financial year 2025-26. The record date serves as the cut-off for determining which investors are entitled to the dividend payment. Corporate Communication The official intimation was signed by Rajasekhar Reddy, Company Secretary and Compliance Officer of Hikal Limited, on February 11, 2026. The company has also notified relevant depositories including Central Depository Services (India) Limited and National Securities Depository Limited, along with the registrar and transfer agent MUFG Intime India Private Limited. This dividend declaration reflects the company's commitment to returning value to shareholders during the ongoing financial year. The record date announcement provides shareholders with clear timeline information for dividend eligibility. Hikal Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, reporting a net loss amid challenging market conditions. The company has now officially confirmed the record date for interim dividend payment following regulatory compliance requirements. Financial Performance Overview The company reported mixed financial performance with revenue growth but profitability challenges during the quarter. Metric: Q3 FY26 Q3 FY25 Change Revenue from Operations: ₹4,943 million ₹4,477 million +10.4% Net Loss/Profit: (₹59 million) ₹173 million Loss Basic EPS: (₹0.48) ₹1.40 Negative For the nine months period, the company faced revenue decline with total revenue from operations at ₹11,932 million compared to ₹13,074 million in the previous year, representing a decrease of 8.7%. Segment-wise Performance Both business segments showed mixed results during the quarter: Segment: Q3 FY26 Revenue Q3 FY25 Revenue Change Pharmaceuticals: ₹3,373 million ₹2,934 million +15.0% Crop Protection: ₹1,570 million ₹1,543 million +1.7% The pharmaceuticals segment showed stronger growth momentum despite facing regulatory challenges, while the crop protection segment maintained steady performance. Official Record Date Confirmation Following the board meeting held on February 11, 2026, Hikal Limited has formally communicated the record date details to stock exchanges under Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Parameter: Details Record Date: Tuesday, February 17, 2026 Purpose: Interim Dividend for FY 2025-26 Board Approval Date: February 11, 2026 Exchange Notification: BSE (524735) & NSE (HIKAL) The company has notified Central Depository Services (India) Limited, National Securities Depository Limited, and registrar MUFG Intime India Private Limited regarding the record date fixation. Dividend Declaration Details The Board of Directors had earlier declared an interim dividend for shareholders: Parameter: Details Interim Dividend Rate: 10% (₹0.20 per share) Face Value: ₹2.00 per share Payment Date: On or before March 12, 2026 Regulatory Compliance and Trading Window The formal intimation was signed by Company Secretary & Compliance Officer Rajasekhar Reddy, ensuring compliance with regulatory requirements. The trading window for designated persons will reopen on February 14, 2026, following the closure since January 1, 2026. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.